Faron Pharmaceuticals Oy Stock price

Equities

FARN

FI4000153309

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:22 2024-03-28 pm EDT 5-day change 1st Jan Change
137.5 GBX -1.79% Intraday chart for Faron Pharmaceuticals Oy -7.09% -54.92%
Sales 2023 - Sales 2024 * 18M 19.43M Capitalization 112M 121M
Net income 2023 -30M -32.38M Net income 2024 * -6M -6.48M EV / Sales 2023 -
Net Debt 2023 6.02M 6.5M Net Debt 2024 * 13.43M 14.5M EV / Sales 2024 * 6.99 x
P/E ratio 2023 *
-5.27 x
P/E ratio 2024 *
-7.78 x
Employees 34
Yield 2023 *
-
Yield 2024 *
-
Free-Float 58.18%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Faron Pharmaceuticals Oy

1 day-3.57%
1 week-8.78%
Current month+5.88%
1 month+8.00%
3 months-58.33%
6 months-57.14%
Current year-55.74%
More quotes
1 week
135.00
Extreme 135
155.00
1 month
120.00
Extreme 120
200.00
Current year
120.00
Extreme 120
320.00
1 year
120.00
Extreme 120
370.00
3 years
120.00
Extreme 120
495.00
5 years
54.50
Extreme 54.5
595.00
10 years
50.00
Extreme 50
890.00
More quotes
Managers TitleAgeSince
Founder - 02-12-31
Founder 46 02-12-31
Founder 70 02-12-31
Members of the board TitleAgeSince
Chairman 67 15-09-15
Founder 70 02-12-31
Director/Board Member 60 23-03-23
More insiders
Date Price Change Volume
24-03-28 137.5 -1.79% 14 979
24-03-27 140 -1.75% 10,515
24-03-26 142.5 -1.72% 89,665
24-03-25 145 0.00% 41,486
24-03-22 145 -2.03% 23,497

Delayed Quote London S.E., March 28, 2024 at 04:26 am EDT

More quotes
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron's drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.634 EUR
Average target price
11.6 EUR
Spread / Average Target
+610.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Faron Pharmaceuticals Oy - London S.E.